B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SCN8A

MOLECULAR TARGET

sodium voltage-gated channel alpha subunit 8

UniProt: Q9UQD0NCBI Gene: 63346 compounds

SCN8A (sodium voltage-gated channel alpha subunit 8) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SCN8A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1tetrodotoxin3.1422
2pf 050897712.4010
3Saxitoxin1.102
4Veratridine0.691
5bdb n 7 3r 5r 7r adamantan 1 ylmethoxy 6 cyclopropyl 1 2 4 triazolo 4 3 a pyridin 3 0.691
6bdb n 7 adamantan 1 ylmethoxy 6 ethyl 1 2 4 triazolo 4 3 a pyridin 3 yl cyclopropane0.691

About SCN8A as a Drug Target

SCN8A (sodium voltage-gated channel alpha subunit 8) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented SCN8A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SCN8A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.